Physician

Cynthia Luna-Salazar, MD

According to 2025 Medicare claims, Cynthia Luna-Salazar, MD (NPI: 1598967366) practices internal medicine in the Brownsville-Harlingen, TX market, with the plurality of this provider's patient population coming from Cameron, TX. This provider's primary affiliated billing organization is CYNTHIA LUNA-SALAZAR, MD, PA (NPI: 1992033823; TIN: 271135719) and primary practice location at 78550-8306. Luna-Salazar is affiliated with the Buena Vida y Salud LLC (ACO ID: A2142), participating under the MSSP model.

Luna-Salazar's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 505 traditional Medicare patients, billed 6,202 HCPCS/CPT codes, and received $292,837 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 9,790 prescription claims across 714 beneficiaries totaling $1,530,720 in drug costs, led by Jardiance (Empagliflozin). DME data shows 363 claims. Open Payments data shows 8 records totaling $162. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Similarly, Part D prescription costs have changed little. In contrast, DME billing represents a smaller volume and declined steadily, from $20,355 to $8,716.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	522	5,525	$242,838
2016	518	6,436	$267,036
2017	543	6,341	$275,262
2018	529	5,516	$279,665
2019	560	5,450	$308,044
2020	528	3,628	$269,839
2021	614	4,029	$283,887
2022	509	3,841	$292,623
2023	466	3,207	$243,457
2024	505	6,202	$292,837

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	483	11,857	$1,081,788
2016	485	12,088	$1,122,707
2017	503	11,647	$1,146,430
2018	545	11,036	$1,135,667
2019	580	11,401	$1,206,159
2020	622	11,608	$1,276,273
2021	609	9,789	$1,227,290
2022	614	9,314	$1,469,221
2023	589	9,046	$1,475,867
2024	714	9,790	$1,530,720

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	254	902	$28,715
2016	273	857	$25,592
2017	187	966	$20,000
2018	218	939	$19,755
2019	160	658	$13,616
2020	134	633	$11,840
2021	114	514	$12,374
2022	79	485	$9,791
2023	62	348	$11,329
2024	61	363	$5,293

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	438	1,332	$83
99203	New patient office or other outpatient visit with low level of medical decision making, if using time, 30 minutes or more	82	82	$66
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	212	412	$59
96372	Injection of drug or substance under skin or into muscle	99	202	$9
36415	Insertion of needle into vein for collection of blood sample	192	300	$9

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Jardiance	Empagliflozin	278	13,498	$247,271
Ozempic	Semaglutide	194	7,636	$228,967
Mounjaro	Tirzepatide	157	4,790	$172,358
Velphoro	Sucroferric Oxyhydroxide	32	1,200	$93,550
Januvia	Sitagliptin Phosphate	70	4,392	$75,617

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
E0601	Continuous positive airway pressure (cpap) device	Y	N/R	25	$958
A4253	Blood glucose test or reagent strips for home blood glucose monitor, per 50 strips	N	35	79	$946
J7500	Azathioprine, oral, 50 mg	N	N/R	12	$873
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	40	$702
J7507	Tacrolimus, immediate release, oral, 1 mg	N	N/R	27	$469

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	8	$162	Boehringer Ingelheim Pharmaceuticals, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Cynthia Luna-Salazar, MD?

Tedicare shows public-source Medicare data for Cynthia Luna-Salazar, MD (NPI 1598967366), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Cynthia Luna-Salazar, MD have ACO affiliation data?

Cynthia Luna-Salazar, MD is shown with ACO affiliation data for Buena Vida y Salud LLC (MSSP, ACO ID A2142).

What billing organization is linked to Cynthia Luna-Salazar, MD?

Cynthia Luna-Salazar, MD is linked to CYNTHIA LUNA-SALAZAR, MD, PA (billing NPI 1992033823) in the available physician profile data.

Does Cynthia Luna-Salazar, MD have Open Payments data?

Cynthia Luna-Salazar, MD has 8 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.